IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v11y2020i1d10.1038_s41467-020-15436-0.html
   My bibliography  Save this article

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

Author

Listed:
  • Shorena Janelidze

    (Lund University)

  • Erik Stomrud

    (Lund University)

  • Ruben Smith

    (Lund University
    Skåne University Hospital)

  • Sebastian Palmqvist

    (Lund University
    Skåne University Hospital)

  • Niklas Mattsson

    (Lund University
    Skåne University Hospital
    Lund University)

  • David C. Airey

    (Eli Lilly and Company)

  • Nicholas K. Proctor

    (Eli Lilly and Company)

  • Xiyun Chai

    (Eli Lilly and Company)

  • Sergey Shcherbinin

    (Eli Lilly and Company)

  • John R. Sims

    (Eli Lilly and Company)

  • Gallen Triana-Baltzer

    (Janssen Research & Development)

  • Clara Theunis

    (Janssen Pharmaceutical Companies of Johnson & Johnson)

  • Randy Slemmon

    (Janssen Research & Development)

  • Marc Mercken

    (Janssen Pharmaceutical Companies of Johnson & Johnson)

  • Hartmuth Kolb

    (Janssen Research & Development)

  • Jeffrey L. Dage

    (Eli Lilly and Company)

  • Oskar Hansson

    (Lund University
    Skåne University Hospital)

Abstract

Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer’s disease (AD), reflecting abnormal tau metabolism in the brain. Here we investigate the performance of CSF p-tau217 as a biomarker of AD in comparison to p-tau181. In the Swedish BioFINDER cohort (n = 194), p-tau217 shows stronger correlations with the tau positron emission tomography (PET) tracer [18F]flortaucipir, and more accurately identifies individuals with abnormally increased [18F]flortaucipir retention. Furthermore, longitudinal increases in p-tau217 are higher compared to p-tau181 and better correlate with [18F]flortaucipir uptake. P-tau217 correlates better than p-tau181 with CSF and PET measures of neocortical amyloid-β burden and more accurately distinguishes AD dementia from non-AD neurodegenerative disorders. Higher correlations between p-tau217 and [18F]flortaucipir are corroborated in an independent EXPEDITION3 trial cohort (n = 32). The main results are validated using a different p-tau217 immunoassay. These findings suggest that p-tau217 might be more useful than p-tau181 in the diagnostic work up of AD.

Suggested Citation

  • Shorena Janelidze & Erik Stomrud & Ruben Smith & Sebastian Palmqvist & Niklas Mattsson & David C. Airey & Nicholas K. Proctor & Xiyun Chai & Sergey Shcherbinin & John R. Sims & Gallen Triana-Baltzer &, 2020. "Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease," Nature Communications, Nature, vol. 11(1), pages 1-12, December.
    • Handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-15436-0
    DOI: 10.1038/s41467-020-15436-0
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-020-15436-0
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-020-15436-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Anna L. Wojdała & Giovanni Bellomo & Lorenzo Gaetani & Charlotte E. Teunissen & Lucilla Parnetti & Davide Chiasserini, 2025. "Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer’s disease biomarkers," Nature Communications, Nature, vol. 16(1), pages 1-11, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-15436-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.